2012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day. Critical Path Institute , a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does. C-Path Milestones and “firsts” include: 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely. 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data. 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes. 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials. 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials. C-Path brings together stakeholders to create what no one company, university, or government agency could do alone: 6 global consortia with 1,000 scientists, 41 companies, government agencies, patient groups, and academia to collaborate on “tools” to help drug development and focus on drug safety, drug effectiveness, diseases of the brain, developing new imaging biomarkers, and testing drug combinations. C-Path’s collaborative work is just beginning to translate knowledge of disease and human physiology into safe and effective therapies.
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
Jennifer Kehlet Barton, PhD, 2012 Bioscience Educator of the Year
Jennifer Kehlet Barton, Ph.D., Associate Vice President for Research and Professor, Biomedical Engineering at The University of Arizona was named the 2012 Michael A. Cusanovich Bioscience Educator of the Year by the Arizona Bioindustry Association. Dr. Barton was nominated by students, past and present with supporting nominations by her co-workers, and selected for this honor by an independent panel of judges from across the state of Arizona for her contributions to all aspects of bioscience education. They include her skill as a course instructor, her compassion and patience as a mentor and adviser to undergraduate and graduate students, her strategic leadership in creating a learning environment and career path for students via her development and leadership of the UA Biomedical Engineering Programs, her recent role as Assistant Director of the BIO5 Institute, and her participation with industry in a broad range of industry association and community groups.
Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury , lecturing around the United States and the world. Now he joined Phoenix Children's to expand a program that surpasses the typical model of pediatric care. For some, it's playing a musical instrument. For others, it's painting. But for P. David Adelson, MD, FACS, FAAP, the director of the Hospital's Barrow Neurological Institute and chief of neurosurgery, his passion is a bit atypical. "My hobby is neuroscience," he says. "The heart's a pump, the kidney's a filter – those are all simple functions which are there to support who we are and what we do." But the brain controls it all, he says. "I just looked at the brain and neurosciences as the next frontier; studying something of which I would never get bored." Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury clinical management, lecturing around the United States and the world. He has been published in numerous medical and scientific journals defining "state-of-the art" in the care of children with traumatic brain injuries. The path to Phoenix Children's Hospital Dr. Adelson came to Phoenix in January from Pittsburgh, where he served as the A. Leland Albright Endowed Professor of Neurosurgery/Pediatric Neurosurgery at Children's Hospital of Pittsburgh and Vice Chairman, (Research) at the University of Pittsburgh School of Medicine , one of the most prominent neurosurgical departments in the country.
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona Panelists Bob Bosserman, CEO, Medelis Janet Spear, Plant Manager, Celgene Joan Koerber-Walker, president & CEO, AZBio (moderator) Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley Dr. Phil Miller, Ventana Filmed live at the 2011 AZBio Expo